JNJJohnson & Johnson

$261.45+53% 1Y

$261.45

$171.2152 weeks$278.28

Is the price fair?

Fair

Neither cheap nor expensive: nothing decisive, though at the top of its own P/E range.

1 to watch, 1 neutral, 1 without data

What the price assumes~+8% a yearderived · Jun 28, 2026

Priced for ~8% a year FCF growth. Roughly in line with its three-year revenue growth of 6% a year.

Vs its own P/E rangedearer than 92% of its own historyderived

Expensive vs its own history: P/E 30.3 vs a 20.3 median over 39 quarters (+49% vs median).

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 68% of the market

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Johnson & Johnson trades at 30.3× earnings against 26.2× for the median Drug Manufacturers - General name, more expensive than its own group.

30.3

Trailing P/E · Drug Manufacturers - General median 26.2 · 1.16× the median: the market pays up for this one

Price / sales: 5.61
Price / sales · today's price, trailing year to Jun 28, 2026
Free cash flow yield: 4.0%
Free cash flow yield · Drug Manufacturers - General median 5.7%
Growth the price implies: +8.5%
Growth the price implies · The price pays for +8.5% free cash flow growth a year for a decade; the business has delivered +15% a year over the last three.

Details›

What the market has paid for these earnings: 39 quarters of its own multiple × $8.62 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$147.52
Its own P/E history, median	$175.17
Its own P/E history, upper quartile	$205.60
52-week range	$171.21 – $278.28
Today	$261.45

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

The closest names by size in the same industry